...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Question on valuing shares from time of spinoff

I think Zenith will have to provide a statement on the initial share cost, as RVX did for RVX.  I don't think the brokerage numbers are worth anything.  Mine shows a cost of 14¢ CAD and a current value of 50¢ USD.

Share
New Message
Please login to post a reply